Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. (PRTK) Revenue
Annual & quarterly revenue history · segment & region breakdown
PRTK · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsParatek Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.17B, an increase of 24.67% year-over-year from $0.15B in FY2022.
Revenue trend
2022 – 2003 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.15B | +$0.03B | +24.67% |
| 2021-12-31 | $0.12B | +$0.08B | +177.94% |
| 2020-12-31 | $0.04B | +$0.03B | +163.04% |
| 2019-12-31 | $0.02B | -$0.00B | -3.35% |
| 2018-12-31 | $0.02B | +$0.00B | +35.68% |
| 2017-12-31 | $0.01B | +$0.01B | +43403.45% |
| 2016-12-31 | $0.00B | +$0.00B | — |
| 2015-12-31 | $0.00B | -$0.00B | -100.00% |
| 2014-12-31 | $0.00B | +$0.00B | +148.54% |
| 2013-12-31 | $0.00B | -$0.01B | -84.16% |
Compare revenue vs peers
BiotechnologyCompare PRTK revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Paratek Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Paratek Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Paratek Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PRTK revenue · 4 questionsPRTK's trailing twelve-month (TTM) revenue is $0.17B. That is an increase of 24.67% year-over-year from $0.15B in FY2022.
▸ Source: FMP · Paratek Pharmaceuticals, Inc. SEC filings · GAAP · Paratek Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026